Omental metastasis as a predictive risk factor for unfavorable prognosis in patients with stage III–IV epithelial ovarian cancer

• Published in: International journal of clinical oncology 2021-05, Vol.26 (5), p.995-1004
• Main Authors: Iwagoi, Yutaka, Motohara, Takeshi, Hwang, Sangyoon, Fujimoto, Koichi, Ikeda, Tokunori, Katabuchi, Hidetaka
• Format: Article
• Language: English
• Subjects: Cancer Research; Chemoresistance; Chemotherapy; Medical prognosis; Medicine; Medicine & Public Health; Metastases; Metastasis; Multivariate analysis; Omentum; Oncology; Original; Original Article; Ovarian cancer; Patients; Prognosis; Risk factors; Statistical analysis; Surgery; Surgical Oncology; Survival
• ISSN: 1341-9625; 1437-7772
• DOI: 10.1007/s10147-021-01866-3

Background Epithelial ovarian cancer has a clear predilection for the omentum as the site of metastasis; however, its contribution to clinical outcomes remains unresolved. This study aimed to evaluate the prognostic significance and efficacy of chemotherapy in the presence of omental metastasis. Methods A retrospective cohort study was performed in 56 patients with stage III–IV ovarian cancer who underwent primary debulking surgery between 2004 and 2018 at Kumamoto University Hospital. Results Thirty-six (64.3%) patients were categorized into the omental metastasis-positive group, whereas 20 (35.7%) patients were in the omental metastasis-negative group. The 5-year overall survival rates were 43.4% in the omental metastasis-positive group and 93.8% in the omental metastasis-negative group. Statistically significant differences were observed in overall survival ( p  = 0.002) and progression-free survival ( p  = 0.036) between the omental metastasis-positive and metastasis-negative groups. Notably, multivariate analysis demonstrated that the existence of omental metastasis is an independent risk factor for overall survival in patients with stage III–IV ovarian cancer (hazard ratio 8.90, 95% confidence interval 1.16–69.77; p  = 0.038). Furthermore, the omental metastasis-positive group had significantly lower overall response rates to chemotherapy for recurrent disease, compared to the omental metastasis-negative group (31.6% vs. 85.7%, p  = 0.026). Conclusion Our present data demonstrated that omental metastasis is closely associated with an unfavorable prognosis due to increased chemoresistance in patients with stage III–IV ovarian cancer. Elucidating the biological mechanism of omental metastasis will shed light on novel therapeutic approaches for the management of advanced ovarian cancer patients.